Status:
UNKNOWN
Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
CSL Behring
Conditions:
Anticoagulation
Anticoagulation Reversal
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Prospective assessment of vitamin K dependent coagulation factor levels after temporary warfarin reversal in participants with left ventricular assist devices (LAVD).
Detailed Description
Prospective evaluation of the levels of the vitamin K dependent coagulation factors 2,7,9,10, and proteins C and S, in patients on warfarin treated with four factor prothrombin complex concentrate (4F...
Eligibility Criteria
Inclusion
- LVAD on warfarin requiring temporary interruption of anticoagulation for procedures
Exclusion
- recent thrombotic event
Key Trial Info
Start Date :
March 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03473132
Start Date
March 15 2018
End Date
March 31 2022
Last Update
May 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115